RESOLVING THE LEDGER
This is one outlet's own report from Yahoo Finance — the article as it was filed. Other outlets are covering the same event; open the full story to compare every source side by side.
See the full story · 1 sources
Liquidia (LQDA) topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits amid an ongoing rivalry with United Therapeutics (UTHR). Yutrepia and United's Tyvaso are inhaled treatments for forms of high blood pressure in the lungs. During the June quarter, Yutrepia generated $170.4 million in sales, growing 31% and beating the Street's…
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
AIPROPX is an independent multi-source news index — we track, compare, and connect coverage from across the web into one place you won't find anywhere else.